Lyell Immunopharma, Inc. Common Stock (LYEL) is a publicly traded Healthcare sector company. As of November 2, 2026, LYEL trades at $11.05 with a market cap of $270.54M and a P/E ratio of -0.68. LYEL moved +2.90% today. Year to date, LYEL is -61.90%; over the trailing twelve months it is -33.21%. Its 52-week range spans $7.20 to $45.00. Analyst consensus is buy with an average price target of $36.20. Rallies surfaces LYEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LYEL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LYEL recently traded at $11.05. Market cap is $270.54M. P/E ratio is -0.68. Revenue is $27.00K.
| Metric | Value |
|---|---|
| Price | $11.05 |
| Market Cap | $270.54M |
| P/E Ratio | -0.68 |
| EPS | $-12.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.00 |
| 52-Week Low | $7.20 |
| Volume | 19.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $27.00K |
| Net Income | $-248.48M |
| Gross Margin | 0.00% |
5 analysts cover LYEL: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $36.20.